Trial
NCT02402036
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Georgetown University
Collaborators
Bayer
Condition
Colon Cancer
Intervention
Regorafenib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-29